Kornitzer Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Kornitzer Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,270	Closed	-$565K	–	505
2025 Q2	$565K	Hold	10,270	–	–	0.01%	443
2025 Q1	$726K	Buy	10,270 +2,300	+29%	+$155K	0.02%	399
2024 Q4	$524K	Hold	7,970	–	–	0.01%	427
2024 Q3	$560K	Buy	7,970 +1,850	+30%	+$155K	0.01%	428
2024 Q2	$504K	Sell	6,120 -42,398	-87%	-$3.53M	0.01%	436
2024 Q1	$4.24M	Hold	48,518	–	–	0.08%	266
2023 Q4	$4.68M	Buy	+48,518	New	+$4.29M	0.09%	257
2020 Q3	–	Sell	-159,651	Closed	-$19.7M	–	490
2020 Q2	$19.7M	Buy	+159,651	New	+$15.9M	0.4%	84
2015 Q1	–	Sell	-154,600	Closed	-$14M	–	451
2014 Q4	$14M	Sell	154,600 -27,100	-15%	-$2.25M	0.16%	150
2014 Q3	$13.1M	Sell	181,700 -200	-0.1%	-$13.1K	0.15%	157
2014 Q2	$11.3M	Buy	181,900 +169,300	+1,344%	+$10.2M	0.12%	182
2014 Q1	$859K	Buy	+12,600	New	+$929K	0.01%	364

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Kornitzer Capital Management's BMRN Position: Q3 2025 in Review

Kornitzer Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2025, closing a stake of 10,270 shares — an estimated $565K sold.

Kornitzer Capital Management first reported a position in BMRN in Q1 2014 and held it in 12 quarters. The position peaked at $19.7M in Q2 2020. 576 funds tracked by Wall St. Rank hold BMRN as of Q3 2025.

Kornitzer Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Kornitzer Capital Management sold 10,270 BioMarin Pharmaceuticals shares in Q3 2025, an estimated $565K.
Kornitzer Capital Management first reported a position in BioMarin Pharmaceuticals in Q1 2014 and held it in 12 quarters.
Kornitzer Capital Management's BioMarin Pharmaceuticals position peaked at $19.7M in Q2 2020.
576 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2025.

Based on Kornitzer Capital Management's 13F filing for Q3 2025, filed 31 Oct 2025.